Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande, John K. Chan, Minal Barve, Jonathan Oh, Devansu Tewari, Peter C. Morris, Erin Stevens, Justin Bottsford-Miller, Min Tang, Phylicia Aaron, Laura Stanbery, Staci Horvath, Gladice Wallraven, Ernest Bognar, Luisa Manning, John Nemunaitis, David Shanahan, Brian M. Slomovitz, Thomas J. Herzog, Bradley J. Monk, Robert L. Coleman